Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$127000.0.

  • CytomX Therapeutics' Capital Expenditures fell 76842.11% to -$127000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $99000.0, marking a year-over-year decrease of 8004.03%. This contributed to the annual value of $310000.0 for FY2024, which is 6309.52% down from last year.
  • Per CytomX Therapeutics' latest filing, its Capital Expenditures stood at -$127000.0 for Q3 2025, which was down 76842.11% from $27000.0 recorded in Q2 2025.
  • CytomX Therapeutics' Capital Expenditures' 5-year high stood at $982000.0 during Q1 2021, with a 5-year trough of -$127000.0 in Q3 2025.
  • In the last 5 years, CytomX Therapeutics' Capital Expenditures had a median value of $119000.0 in 2025 and averaged $237789.5.
  • Per our database at Business Quant, CytomX Therapeutics' Capital Expenditures surged by 26140.35% in 2022 and then tumbled by 76842.11% in 2025.
  • Over the past 5 years, CytomX Therapeutics' Capital Expenditures (Quarter) stood at $245000.0 in 2021, then fell by 25.71% to $182000.0 in 2022, then soared by 46.15% to $266000.0 in 2023, then plummeted by 69.92% to $80000.0 in 2024, then tumbled by 258.75% to -$127000.0 in 2025.
  • Its Capital Expenditures was -$127000.0 in Q3 2025, compared to $27000.0 in Q2 2025 and $119000.0 in Q1 2025.